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Results: Whereas for machines younger than 10 years 
agreement between measured and stated dose was 90% 
overall, for those over 30 years old agreement dropped to 
70%. However, this picture varied with region. Linac 
dosimetry was always better than 60Co and multi-machine 
centres generally performed better than single machine 
institutions. We interpret this latter observation as a 
reflection of a more substantial physics infrastructure in 
larger centres. The data suggest virtually no dependence on 
the time elapsed since the last dosimetry system calibration 
at least out to 10 years. Second or subsequent participation 
in audits reflected higher quality dosimetry (85% of results 
within the XX's acceptance criterion) than the first audit 
(77%). The use of ND,w based dosimetry protocols resulted in 
more accurate dosimetry than the use of the older Nk or Nx 
protocols (95%, 92% and 79% agreement respectively). 
Conclusions: Clearly, over the 45 years that the XX has 
accumulated these TLD data, practice has changed both in 
institutions and at the XX's Dosimetry Laboratory. However, it 
is possible to draw some general conclusions from the 
analysis. Higher quality dosimetry is generally associated with 
younger machines, linacs as opposed to 60Co, centres with 
more than one machine, prior experience with the XX's audit 
programme and the use of an ND,w based protocol.  
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Purpose/Objective: To evaluate the dosimetric properties of 
the synthetic diamond dosimeter PTW 60019 (microDiamond) 
in high-energy scanned clinical carbon ion beams.  
Materials and Methods: The measurements were performed 
at the National Center for Oncological Treatment (CNAO) 
synchrotron facility. The detector response was tested under 
actively scanned carbon ion beams ranging from 115 to 380 
MeV/u. All measurements were performed in a water 
phantom. The detector performance was firstly evaluated in 
terms of response stability, dependence on beam energy and 
ion type (carbon ions and protons), linearity with dose, dose 
rate and angular dependence. The depth dose curve of a 280 
MeV/u carbon ion beam, obtained by the microDiamond 
detector was compared to the one measured using a PTW 
Advanced Markus ionization chamber, and to numerical 
simulation from FLUKA Monte Carlo code. Dose 
measurements in spread-out-Bragg-peaks (SOBP) were also 
performed and the results were compared to the data from 
the treatment planning system (TPS). 
Results: A response reproducibility within about 1% was 
found. Deviations of the calibaration factor below 3.5% with 
respect to the reference Co-60 source were observed for the 
whole set of beam qualities investigated (including protons). 
The detector response showed a good linear behavior and its 
sensitivity was found to be dose rate independent, with a 
variation below 1.3% in the evaluated dose rate range. Very 
good agreement between the measured Bragg peak curves, 
with respect both to the ones obtained by the Advanced 
Markus chamber and to simulated ones were observed, 
demonstrating a substantial LET independence of the 
microDiamond response. Very good results were also obtained 
from SOBP measurements, with a difference below 1% 
between measured and TPS-calculated doses.  
Conclusions: The results of the present study showed that 
the microDiamond detector is suitable for clinical carbon ion 
beams dosimetry.  
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Purpose/Objective: Flattening filter free (FFF) beams are 
becoming the new gold standard modality for clinical 
stereotactic body radiotherapy (SBRT). Beneficial 
characteristics compared to conventional flattened fields 
(FF) include higher dose rate, reduced lateral changes in 
beam hardening, reduced leakage, and less out-of-field dose 
and these have the potential to improve treatment plans. 
The two main accelerator manufacturers have chosen to 
implement FFF with different energy definitions and are 
using quite different MLC designs, which might also influence 
the achievable plan quality, as might the use of different 
treatment planning systems (TPS) with different MLC 
segmentation algorithms. This study investigates the 
possibility of creating FFF plans with high dose delivery 
accuracy across the different vendors, energies, and TPSs 
used for planning. 
Materials and Methods: Ten lung patient cases were 
provided to seven different cancer treatment centres for 
SBRT planning using FF and FFF beams. The different centres’ 
linac/TPS combinations were: Varian-Eclipse, Varian-
Pinnacle, Novalis-Eclipse, Elekta-Pinnacle and Elekta-Monaco. 
All planning followed the same protocol. The prescribed 
minimum dose was 48Gy/4fr for tumours located less than 
1.5cm from the thorax wall, 50Gy/5fr for tumours located 
within 2cm of the main bronchial tree, and 54Gy/3fr for free 
lying tumours in the lung. Half circle VMAT arcs were used for 
all plans avoiding the contra lateral lung. All treatment plans 
were delivered and measured using the Sun Nuclear ArcCheck 
phantom and evaluated using a 3% and 3 mm gamma analysis 
between planned and measured doses. Beam on times were 
recorded for the treatment beams. All DVH metrics were 
tested for significant differences with a paired two-sided 
Wilcoxon-signed rank test, with a significance level of 5%. 
Results: All the linac-TPS combinations show high dose 
accuracy across the ten patients, with a mean pass rate of 
98.1% and 97.4% for FF and FFF treatment plan respectively 
(see table). For the Elekta-Pinnacle combination the FFF 
plans have lower pass rates than FF plans, which might be 
related to the relative calibration of the ArcCheck phantom 
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being performed in low dose rates. The MU used for the FFF 
plans are higher in the Varian/Novalis-Eclipse combination; 
this is not seen for Elekta –Pinnacle. In general Eclipse used 
more MU than Pinnacle. The beam-on times are significantly 
reduced and the largest gain is seen for Elekta-Pinnacle. 
 
 
Conclusions: FFF can be used for SBRT planning and delivery 
of accurate dose, independent of the specific combination of 
accelerator vendor and treatment planning system. The 
different combinations have different specific issues. Future 
perspective is to add the TomoTherapy-Hi Art combination to 
the study. 
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Purpose/Objective: To confirm the heart-sparing ability and 
feasibility of the voluntary breath-hold (VBH) technique in a 
multicentre setting. 
Materials and Methods: Following surgery for early breast 
cancer, patients with any heart inside the 50% isodose on 
free-breathing radiotherapy planning-CT scans with standard 
tangential fields, underwent a second planning-CT scan using 
the VBH technique. Separate radiotherapy treatment plans 
were prepared based on free-breathing and VBH CT scans. 
Mean heart, left anterior descending coronary artery (LAD) 
and lung doses were calculated for each plan. Daily 
electronic portal imaging (EPI) was performed and 
scanning/treatment times were recorded. The primary 
endpoint was the percentage of patients who achieved a 
reduction in mean heart dose with VBH. Population 
systematic (Σ) and random errors (σ) were estimated and 
within-patient comparisons between techniques used 
Wilcoxon signed-rank tests. 
Results: 101 patients from 10 UK centres were recruited. 
Data for the first 43 patients has been analysed and showed 
that 41 (95%) achieved a reduction in mean heart dose with 
VBH. Mean cardiac doses (Gy) for free-breathing and VBH 
techniques were: heart 1.9 and 1.1, LAD 12.1 and 5.7, 
maximum LAD dose 34.5 and 24.8. Pooled EPI-based 
displacement data showed Σ of 1.2-1.7mm and σ 1.6-2.1mm. 
Median CT and treatment session times were 20 and 22 
minutes respectively. 
Conclusions: Preliminary data suggest multicentre 
implementation of VBH is both effective at heart-sparing and 
feasible. Results from the remaining 58 patients are being 
analysed, and complete data (including inter-centre 
comparisons) will be presented in April 2015. 
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Adjuvant radiotherapy reduces the risk of recurrence and 
death for early-stage breast cancer. However in planning 
radiotherapy, dose to the heart should be considered since 
recent data suggest an increasing risk of ischemic heart 
disease with increasing dose to the heart. Conduction 
abnormalities have been reported after mediastinal radiation 
for Hodgkin’s disease, but the risk of conduction disorders 
and arrhythmias does not appear to be increased subsequent 
to breast cancer radiotherapy. Such conduction abnormalities 
constitute a quite heterogenous group covering mild as well 
as severe disorders.  
Purpose 
The aim of this study was to examine the risk of severe 
conduction abnormalities evaluated by implantation of a 
pacemaker, subsequent to breast cancer radiotherapy. 
Materials and Methods: From the database of the Danish 
Breast Cancer Collaborative Group, we identified women 
treated with radiotherapy for early-stage breast cancer in 
Denmark from 1982 to 2005. By record linkage to the Danish 
Pacemaker and ICD Registry information was retrieved on 
pacemaker implants subsequent to radiotherapy. The rate 
ratios (RR) of pacemaker implantation were estimated by 
Poisson regression for left versus right sided breast cancer 
with stratification for calendar year of breast cancer 
diagnosis, age at diagnosis and time since diagnosis (all in 
five-year groups). 95% confidence intervals (CI) and two-sides 
significance tests were calculated.  
Results: Among 18,129 women treated with radiotherapy for 
early-stage breast cancer, 179 women had a pacemaker 
implanted subsequent to radiotherapy, 90 in 9,315 left sided 
and 89 in 8,993 right sided breast cancers. The unadjusted RR 
was 1.02 (0.76-1.36 95% CI, p=0.91) and the RR adjusted for 
year, age and time since diagnosis was 1.06 (0.79-1.42 95% 
CI, p=0.71). 
Conclusions: Adjuvant radiotherapy as practiced in Denmark 
for early stage breast cancer does not increase the risk of 
severe conduction abnormalities in the heart.  
   
